Vial duration

GHRP-2 vial duration calculator

Estimate how many weeks one 5 mg GHRP-2 vial covers at your dose and weekly cadence.

Download Peptide PilotiPhone · Free to download

Total doses

50

Lasts

7.1 weeks

GHRP-2 is a short-acting injectable peptide people use to trigger sharp pulses of their own growth hormone, usually paired with a GHRH like CJC-1295 or sermorelin. It mimics ghrelin at the GH-secretagogue receptor, producing a strong but brief GH spike within minutes of injection. Published studies show clear post-injection GH peaks, with some appetite increase as a side effect. This page covers reconstitution math and per-injection logging cadence.

How the GHRP-2 vial duration calculator works

This calculator answers the inventory question: at your current dose and weekly cadence, how many weeks will this GHRP-2 vial last? It is the math you need to plan refills before a vial runs dry mid-protocol — especially with peptides like GLP-1s where shipping windows can run several weeks.

The formula is two divisions. Total doses per vial equals vial mg divided by dose mg, rounded down. Weeks of supply equals total doses divided by doses per week. With a 5 mg vial of GHRP-2, a 0.1 mg dose, and 7 dose per week, the vial covers 50 doses, or about 7.1 weeks of supply.

The three inputs that move the answer: vial mg (set when you bought the vial), dose mg (set by your protocol step), and doses-per-week (set by the peptide's half-life). Once a vial is reconstituted it also has a stability ceiling — most lyophilized peptides reconstituted in BAC water are typically used within four to six weeks of refrigerated storage, so a vial that mathematically lasts twelve weeks may not last twelve weeks in practice.

Use this calculator before opening a new vial to confirm the dose and cadence you have planned will not strand you halfway through. Use it again whenever you titrate up — a dose increase shortens vial life, sometimes dramatically. The calculator is intentionally conservative: it floors total doses, never assumes partial-dose draws, and never extends weeks beyond what whole doses support.

GHRP-2 cadence and how it changes vial life

Published research on GHRP-2 frequently documents protocols that involve multiple administrations throughout the day, typically ranging from one to three separate doses. This dosing cadence is a direct consequence of the peptide's short half-life, a common characteristic among all synthetic ghrelin agonists that necessitates repeated stimulus to study sustained effects. A standard U-100 insulin syringe is almost universally employed for this purpose, as it provides the necessary precision to accurately measure and draw the small liquid volumes corresponding to typical dose magnitudes of around 100 micrograms.

The timing of administration is a critical variable studied in these protocols, with doses often scheduled on an empty stomach, such as upon waking or several hours after a meal. This timing is planned to prevent the potential blunting effect that circulating glucose and fatty acids can have on the pulsatile release of growth hormone. For anyone documenting a personal protocol, this makes time-stamping each log entry essential. Without this data point, a log of a three-times-daily schedule rapidly degrades into a simple tally that cannot be used to analyze patterns or correlate observed outcomes to a specific morning, mid-day, or evening administration.

A second consideration documented in the comparative literature is how a multi-dose schedule interacts with cumulative weekly exposure. Three 100 mcg doses per day for seven days produce 2,100 mcg of weekly exposure from a single 5 mg vial, which means a vial reconstituted at the example concentration of 2,500 mcg/mL lasts roughly two and a half weeks at that cadence — a useful number to know in advance when planning reorders, since running out mid-cycle disrupts whatever pattern the log was attempting to capture. Researchers who document this kind of long-running protocol typically also note ambient temperature during transport between dose times, because a vial carried in a warm bag for several hours each day is not in the same storage condition as one that lives continuously in a refrigerator, and the difference is worth recording even if the visible appearance of the solution does not change.

Storage and shelf life for GHRP-2

Prior to being reconstituted, the lyophilized powder within the vial is kept in a refrigerated environment to maintain its integrity. After the peptide has been dissolved in a sterile diluent, the resulting solution is also stored under refrigeration. Users typically observe the solution over a period of use that does not exceed a few weeks, monitoring for any visual changes.

Tracking GHRP-2 vials in a real log

For GHRP-2, the single most critical variable to log is the exact time of each administration. Due to study protocols that often involve a one-to-three times daily cadence, a simple dose-and-date entry is insufficient for any form of retrospective analysis. Without a precise timestamp, it becomes impossible to differentiate the effects of a morning dose from a pre-bed dose or analyze how timing relative to meals or other activities might correlate with logged observations. Therefore, meticulously stamping every dose with the hour and minute is paramount to creating a dataset that retains its analytical value over time.

Common GHRP-2 vial-planning mistakes

  • Mistaking GHRP-2 for GHRP-6 and failing to account for the documented differences in their side-effect profiles regarding appetite stimulation and prolactin.
  • Neglecting to log the specific time of day for each dose in a multi-dose schedule, which renders later analysis of the data almost meaningless.
  • Using a large-volume syringe (e.g., a 3 mL syringe) that lacks the fine gradations needed to accurately measure a typical 100 mcg dose volume.
  • Administering a dose immediately following a large meal, a variable noted in research that can interfere with the peptide's primary action.
  • Basing dose calculations on a previous vial's concentration without verifying the milligram amount and diluent volume for the new vial.

Frequently asked questions about GHRP-2 vial duration

How is GHRP-2 structurally different from GHRP-6?
GHRP-2 is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-D-Trp-D-Phe-Lys-NH2. It was developed as a second-generation evolution of GHRP-6. The primary structural difference is the substitution of the natural L-Alanine found in GHRP-6 with a synthetic D-Alanine residue. This single amino acid change significantly alters the molecule’s interaction with the ghrelin receptor, giving rise to its different selectivity profile.
Why do studies describe GHRP-2 as more selective than GHRP-6?
In comparative scientific studies, GHRP-2 has been observed to stimulate a potent release of growth hormone while having a lesser impact on cortisol, prolactin, and appetite compared to dose-equivalent administrations of GHRP-6. This means its action is more focused on GH release. While it targets the same ghrelin receptor, its modified structure results in this more specific downstream effect, though it is still considered less selective than the third-generation peptide ipamorelin.
If a 5 mg vial of GHRP-2 is reconstituted with 2 mL of water, how many units are drawn for a 100 mcg dose?
When a 5 mg (5,000 mcg) vial is reconstituted with 2 mL of diluent, the final concentration becomes 2,500 mcg per mL. To calculate the volume for a 100 mcg dose, you divide the dose by the concentration: 100 mcg ÷ 2,500 mcg/mL equals 0.04 mL. On a U-100 insulin syringe, 0.04 mL corresponds to exactly 4 units.
What is the rationale for the multiple daily administrations sometimes seen in research logs?
Like other peptides in the ghrelin mimetic class, GHRP-2 has a very short biological half-life, meaning its action dissipates quickly after administration. To study the effect of more sustained GH elevation, research protocols often involve scheduling multiple smaller doses throughout the day. This approach contrasts with using a single, larger dose, which would produce a more acute but less frequent pulse.
Why is it so important to log the time of day when documenting a GHRP-2 protocol?
Because study protocols can involve one, two, or three administrations per day, a log entry that only states the date and dose amount is incomplete. A timestamp clarifies if it was a morning dose on an empty stomach, a pre-workout dose, or a pre-bedtime dose. This granular detail is crucial for any meaningful retrospective analysis, as the timing of administration relative to other factors like meals is a key variable.
Does GHRP-2 work through the same mechanism as a GHRH analog like Sermorelin?
No, they operate via completely separate and distinct pathways. GHRP-2 is a ghrelin receptor agonist, mimicking the hormone ghrelin to stimulate the pituitary gland through the GHSR-1a receptor. In contrast, GHRH analogs like Sermorelin work by binding to the Growth Hormone-Releasing Hormone receptor (GHRHR). While both pathways ultimately lead to GH release, they are independent mechanisms.

Related on Peptide Pilot

Track GHRP-2 vials automatically

Download on the App Store